About Humane Genomics
Humane Genomics has developed a platform to engineer cancer killing viruses. We have taken a first principles approach to design and make oncolytic viral therapies. Using a highly lytic RNA virus engineered with "2 factor authentication" (using selective infection and selective replication) they have an on-target to off-target kill ratio > 1000. We are working on our first indication, pediatric liver cancer (hepatoblastoma), with our partners at Texas Children's Hospital, who are world leading experts. We have in vivo (mouse) data showing safety and currently developing efficacy data and are showing 50% reduction in tumor volume.
Founders & Key People
Financials Beta
Business Model: Not Specified
Revenues: Not Specified
Expenses: Not Specified
Debt: Request
Operating Status: Active
Funding Raised: $0
Investment Rounds: 0 Rounds
Funding Stage: Not Specified
Last Funding Date: Not Specified